Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers | Zendy

Hwa-ping Feng | Zendy; Luzelena Caro | Zendy; Christine Fandozzi | Zendy; Xiaoyan Chu | Zendy; Zifang Guo | Zendy; Jennifer Talaty | Zendy; Deborah Panebianco | Zendy; Katherine Dunnington | Zendy; Lihong Du | Zendy; William D. Hanley | Zendy; Iain P. Fraser | Zendy; Anna Mitselos | Zendy; JeanFrançois Denef | Zendy; Inge De Lepeleire | Zendy; Jan de Hoon | Zendy; Corinne Vandermeulen | Zendy; William L. Marshall | Zendy; Patricia Jumes | Zendy; Xiaobi Huang | Zendy; Monika Martinho | Zendy; Robert Valesky | Zendy; Joan R. Butterton | Zendy; Marian Iwamoto | Zendy; Wendy W. Yeh | Zendy

Open Access

Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers

Author(s) -

Hwa-ping Feng,

Luzelena Caro,

Christine Fandozzi,

Xiaoyan Chu,

Zifang Guo,

Jennifer Talaty,

Deborah Panebianco,

Katherine Dunnington,

Lihong Du,

William D. Hanley,

Iain P. Fraser,

Anna Mitselos,

JeanFrançois Denef,

Inge De Lepeleire,

Jan de Hoon,

Corinne Vandermeulen,

William L. Marshall,

Patricia Jumes,

Xiaobi Huang,

Monika Martinho,

Robert Valesky,

Joan R. Butterton,

Marian Iwamoto,

Wendy W. Yeh

Publication year - 2019

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.02142-18

Subject(s) - ritonavir , darunavir , atazanavir , lopinavir , medicine , pharmacology , protease inhibitor (pharmacology) , virology , hepatitis c virus , pharmacokinetics , human immunodeficiency virus (hiv) , viral load , virus , antiretroviral therapy

The combination of the hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor elbasvir and the NS3/4A protease inhibitor grazoprevir is a potent, once-daily therapy indicated for the treatment of chronic HCV infection in individuals coinfected with human immunodeficiency virus (HIV). We explored the pharmacokinetic interactions of elbasvir and grazoprevir with ritonavir and ritonavir-boosted HIV protease inhibitors in three phase 1 trials.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research